Markets
Man With Empty Pockets
Getty Images

Tough times to be a VC

4/12/24 3:32PM

Three years after reaching euphoric highs in 2021, the venture capital market is struggling to regain its footing. Today, The Wall Street Journal reported that venture capitalists (VCs) invested in an estimated 3,925 deals in Q1 2024, down 3% year over year, and well below the 5,466 investments made in Q1 2022.

The Financial Times reported that total capital raised by first-time funds is down from over $40B in 2021 to around $15B in 2023, and even some of Wall Street’s longest-tenured groups are struggling, with Tiger Global only raising $2.2B after initially targeting $6B for its latest fund. Just two years ago, Tiger raised $12.7B for its Fund XV.

So why are VCs struggling to rebound, despite big tech stocks sitting at all-time highs? A few reasons. First, beginning with the Great Financial Crisis, we experienced more than a decade of historically low interest rates, bottoming when the Fed cut rates to almost zero in 2020.

With low interest rates, investors couldn’t get yield from fixed-income investments such as bonds. To generate returns, they had to invest in riskier assets like early-stage startups. With trillions of dollars competing for the same few assets, VCs could easily raise new funds, startup valuations ballooned, and public market demand allowed hundreds of these companies to go public in 2021:

However, with the US federal funds rate now sitting between 5.25 and 5.5%, investors can generate moderate returns from government bonds. When you have a guaranteed 4.5% on a 10 year T-Bill, why would you speculate with a startup that may or may not be worth anything in a few years? Investor capital left venture for other sectors.

For the last decade, startups focused on growth over everything as VCs were willing to continue funding fast-growing, but unprofitable, companies. However, with investor capital slowing, startups had to refocus on profitability, as they could no longer rely on venture capital subsidies. Many startups shut down after failing to make this shift, with financial services platform Carta noting that twice as many well-funded startups on their platform shut down in the first 10 months of 2023 than in all of 2022. Several startups that did survive were forced to raise “down rounds,” or new funding rounds at lower valuations than their previous fundraises.

The entire market is contracting, and it's difficult to see this trend changing without an uptick in private companies successfully going public.

More Markets

See all Markets
markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.